Influence of Zoledronic Acid on Disseminated Tumor Cells in Bone Marrow and Survival: Results of a Prospective Clinical Trial

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2013 Oct 17

PMID 24128322

Citations 42

Authors

Malgorzata Banys

Erich-Franz Solomayer

Gerhard Gebauer

Wolfgang Janni

Natalia Krawczyk

Hans-Joachim Lueck

Sven Becker

Jens Huober

Bernhard Kraemer

Birgit Wackwitz

Peter Hirnle

Diethelm Wallwiener

Tanja Fehm

Affiliations

Soon will be listed here.

Abstract

Background: The presence of disseminated tumor cells (DTC) in bone marrow (BM) of breast cancer patients is associated with reduced clinical outcome. Bisphosphonate treatment was shown to eradicate DTC from BM in several studies. This controlled randomized open-label multi-center study aimed to investigate the influence of zoledronic acid (ZOL) on DTC and survival of breast cancer patients (Clinical Trial Registration Number: NCT00172068).

Methods: Patients with primary breast cancer and DTC-positive bone marrow were randomized to treatment with ZOL plus adjuvant systemic therapy (n = 40) or adjuvant systemic therapy alone (n = 46) between 03/2002 and 12/2004. DTC were identified by immunocytochemistry using the pancytokeratin antibody A45B/B3 and by cytomorphology. The change in DTC numbers at 12 months and 24 months versus baseline, as well as patient outcomes were evaluated.

Results: 86 patients could be included into survival analysis (median follow-up: 88 months, range: 8-108 mths). Patients in the control group were more likely to die during follow-up than those in the ZOL-group (11% vs. 2%, p = 0.106). 15% of patients in the control group presented with relapse whereas only 8% of ZOL group patients developed metastatic or recurrent disease during follow-up (p = 0.205). At 24 months, 16% of patients from the control group were still DTC positive, whereas all patients treated with ZOL became DTC negative (p = 0.032). Patients presenting with persistent DTC 12 months after diagnosis had significantly shorter overall survival (p = 0.011).

Conclusions: Bisphosphonate therapy contributes to eradication of disseminated tumor cells. The positive influence of bisphosphonates on survival in the adjuvant setting may be due to their effects on DTC.

Trial Registration: ClinicalTrials.gov Identifier: NCT00172068 [Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow (MRD-1)].

Citing Articles

Cancer Cells in Sleep Mode: Wake Them to Eliminate or Keep Them Asleep Forever?.

Liu W, Kovacs A, Hou J Cells. 2024; 13(23).

PMID: 39682769 PMC: 11640528. DOI: 10.3390/cells13232022.

Single-Cell Analysis of Bone-Marrow-Disseminated Tumour Cells.

So K, Su Z, Cheung J, Choi S Diagnostics (Basel). 2024; 14(19).

PMID: 39410576 PMC: 11475990. DOI: 10.3390/diagnostics14192172.

Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.

Adams A, Jakob T, Huth A, Monsef I, Ernst M, Kopp M Cochrane Database Syst Rev. 2024; 7:CD013451.

PMID: 38979716 PMC: 11232105. DOI: 10.1002/14651858.CD013451.pub2.

How much do we know about the metastatic process?.

Rodriguez-Tirado C, Sosa M Clin Exp Metastasis. 2024; 41(4):275-299.

PMID: 38520475 PMC: 11374507. DOI: 10.1007/s10585-023-10248-0.

Targeting cancer cell dormancy.

Agudo J, Aguirre-Ghiso J, Bhatia M, Chodosh L, Correia A, Klein C Nat Rev Cancer. 2023; 24(2):97-104.

PMID: 38062251 PMC: 11038906. DOI: 10.1038/s41568-023-00642-x.

References

Banys M, Gruber I, Krawczyk N, Becker S, Kurth R, Wallwiener D . Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2011; 131(3):801-8. DOI: 10.1007/s10549-011-1478-2. View

Solomayer E, Gebauer G, Hirnle P, Janni W, Luck H, Becker S . Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol. 2012; 23(9):2271-2277. DOI: 10.1093/annonc/mdr612. View

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006; 100(2):229-35. DOI: 10.1007/s10549-006-9242-8. View

Bidard F, Kirova Y, Vincent-Salomon A, Alran S, De Rycke Y, Sigal-Zafrani B . Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Ann Oncol. 2009; 20(11):1836-41. DOI: 10.1093/annonc/mdp200. View

Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart J . Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302(3):1055-61. DOI: 10.1124/jpet.102.035295. View

Liotta L, Saidel G, KLEINERMAN J . Stochastic model of metastases formation. Biometrics. 1976; 32(3):535-50. View

Hiraga T, Williams P, Ueda A, Tamura D, Yoneda T . Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004; 10(13):4559-67. DOI: 10.1158/1078-0432.CCR-03-0325. View

Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M . Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010; 11(5):421-8. PMC: 3792651. DOI: 10.1016/S1470-2045(10)70054-1. View

Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino F, Delmas P . Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997; 57(18):3890-4. View

10.

Fournier P, Stresing V, Ebetino F, Clezardin P . How do bisphosphonates inhibit bone metastasis in vivo?. Neoplasia. 2010; 12(7):571-8. PMC: 2907583. DOI: 10.1593/neo.10282. View

11.

Liotta L, Saidel M, KLEINERMAN J . The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976; 36(3):889-94. View

12.

Kraemer B, Rothmund R, Banys M, Krawczyk N, Solomayer E, Mack C . Impaired bone microenvironment: correlation between bone density and presence of disseminated tumor cells. Anticancer Res. 2011; 31(12):4423-8. View

13.

Klein C . Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009; 9(4):302-12. DOI: 10.1038/nrc2627. View

14.

Kristensen B, Ejlertsen B, Mouridsen H, Jensen M, Andersen J, Bjerregaard B . Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol. 2008; 47(4):740-6. DOI: 10.1080/02841860801964988. View

15.

Krag D, Ashikaga T, Moss T, Kusminsky R, Feldman S, Carp N . Breast Cancer Cells in the Blood: A Pilot Study. Breast J. 2001; 5(6):354-358. DOI: 10.1046/j.1524-4741.1999.99016.x. View

16.

Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C . A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer. 2006; 107(5):885-92. DOI: 10.1002/cncr.22076. View

17.

Braun S, Vogl F, Naume B, Janni W, Osborne M, Coombes R . A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353(8):793-802. DOI: 10.1056/NEJMoa050434. View

18.

Winter M, Holen I, Coleman R . Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008; 34(5):453-75. DOI: 10.1016/j.ctrv.2008.02.004. View

19.

Coleman R, Winter M, Cameron D, Bell R, Dodwell D, Keane M . The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010; 102(7):1099-105. PMC: 2853093. DOI: 10.1038/sj.bjc.6605604. View

20.

Becker S, Solomayer E, Becker-Pergola G, Wallwiener D, Fehm T . Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat. 2007; 106(2):239-43. DOI: 10.1007/s10549-006-9484-5. View